Écrit par EMBO | 20 Novembre 2012

HEIDELBERG, 20 November 2012 – Scientists have engineered bacteria that are capable of sacrificing themselves for the good of the bacterial population. These altruistically inclined bacteria, which are described online in the journal Molecular Systems Biology, can be used to demonstrate the conditions where programmed cell death becomes a distinct advantage for the survival of the bacterial...

Écrit par GBI | 15 Novembre 2012

NEW YORK (GBI Research), 15 November 2012 - Intravenous (IV) drips are fast evolving, as patients take their treatment in to the home, states a new report by healthcare experts GBI Research.




The new report* states that diseases such as cancer, Acquired Immune Deficiency Syndrome (AIDS) and Gastrointestinal (GI) disorders are becoming more common, due in part to a globally ageing...

Écrit par GBI | 13 Novembre 2012

NEW YORK (GBI Research), 13 November 2012

Cell culture is becoming the next big pharmaceutical trend, as laboratories rush to meet demand for stem cell and biologics, states a new report by healthcare experts GBI Research. The new report* looks at cell culture, which involves the isolation of animal or plant cells, for their growth in an artificial environment where conditions such as...

Écrit par Aegerion Pharmaceuticals Inc | 31 Octobre 2012

FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of Homozygous Familial Hypercholesterolemia HoFH



October 30 - Aegerion Pharmaceuticals, Inc., une récente start-up de biotech pharmaceutique, dédiée au développement d'un nouveau traitement de l'hypercholestérolémie familiale homozygote (HoFH), maladie  rare très invalidante et souvent mortelle, annonce que...